Laura E. Niklason - Dec 8, 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: President, CEO and Director, Director
Signature: /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Dec 8, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/12/2023, 04:09 PM
Previous filing: Oct 10, 2023
Next filing: Jun 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award	$0	+803K		$0.00	803K	Dec 8, 2023	Common Stock	803K	$2.80	Direct	F1
transaction	HUMA	Stock Options (right to buy)	Award	$0	+525	+33.33%	$0.00	2.1K	Dec 11, 2023	Common Stock	525	$10.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.
F2	On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.

Content

The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.

On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant.